newsfilter
← Latest News
GlobeNewswire·

ADARx Pharmaceuticals to Present at the UBS Global Biopharma Conference

  • ADARx Pharmaceuticals announced that CEO Zhen Li, Ph.D. will participate in a fireside chat at the UBS Global Biopharma Conference in London on Monday, November 16 at 2:00 p.m. GMT.
  • A live webcast of the event will be accessible via the company's investor website, with a replay archived for 90 days.
  • ADARx is a late-stage clinical biotechnology company developing next-generation siRNA therapeutics to treat a broad spectrum of diseases.
  • The company's pipeline includes three clinical-stage hepatic programs: agazisiran, onvuzosiran, & ADX-626.
  • ADARx also has two advanced preclinical extrahepatic programs: ADX-077 & ADX-199.
  • The company intends to leverage its proprietary technologies to expand its pipeline of selective RNA targeted therapies.
  • Investor inquiries can be directed to ir@adarx.com, while media inquiries should contact teri@redhousecomms.com.